Although many reports have demonstrated decreased ADAMTS13 activity and increased von Willebrand factor (VWF) in patients with COVID-19 [59,60], ADAMTS-13 activity was not less than 10% in COVID-19 and the clinical usefulness of a mild decrease in ADAMTS-13 is not clear. The gene discussed is VWF; the disease is COVID-19.